Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 3


ASCO 2022 updated results of the TheraP trial a randomized comparison of 177Lu-PSMA-617 (LuPSMA) and cabazitaxel in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel chemotherapy, Michael Hofman

  • 123456 Profile photo of Madelyn

    Cabazitaxel vs. Lu-PSMA – no difference in OS but better patient reported outcomes. Will probably be preferred treatment post taxane and AR-targeted agents.